SPEER-4F Inhibitors
SPEER-4F inhibitors represent a class of chemical compounds designed to interact with specific biological targets known as SPEER-4F, which is an acronym for a particular molecular structure or function within a cell. These inhibitors are synthetic or natural molecules that have been crafted through a comprehensive understanding of molecular biology, chemistry, and structural biology. By focusing on the SPEER-4F, these inhibitors are able to bind or otherwise modulate the activity of their target. The design and development of SPEER-4F inhibitors involve intricate processes that include the identification of the active site of the SPEER-4F, understanding the mechanism of its action at the molecular level, and creating molecules that can effectively and selectively interact with this site. The specificity of SPEER-4F inhibitors is a result of meticulous chemical engineering, aimed at ensuring that these molecules fit precisely within the targeted domain, much like a key fits into a lock.
The specificity and selectivity of SPEER-4F inhibitors are paramount, as they dictate the efficiency and the profile of interaction with the SPEER-4F. Researchers often utilize techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling to determine the three-dimensional structure of SPEER-4F and to design inhibitors that can achieve a high degree of fit and interaction. These inhibitors often exhibit a high affinity for the SPEER-4F, meaning they are capable of binding to their target with considerable strength, which is quantified by their binding constants. The molecular interactions involved can include hydrogen bonding, hydrophobic forces, van der Waals interactions, and sometimes covalent bonding, which all contribute to the stability and duration of the inhibitor's action. The chemical composition of SPEER-4F inhibitors can vary greatly, from smaller, simpler molecules to large, complex structures, each with a unique set of physicochemical properties that influence their behavior within the biological context. The development of these inhibitors is a testament to the advancements in the fields of chemical synthesis and biochemistry, which enable the precise manipulation of molecules to achieve desired interactions with specific proteins or enzymes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is known to be involved in the proliferation and survival of cancer cells and in other diseases. By inhibiting EGFR, gefitinib can reduce the activity of downstream signaling pathways that may lead to the functional inhibition of SPEER-4F if SPEER-4F were influenced by these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that acts by binding to FK506-binding protein (FKBP12) and then to mTOR complex 1 (mTORC1), inhibiting its activity. Since mTORC1 is involved in protein synthesis and other cellular growth processes, its inhibition could indirectly decrease the functional activity of SPEER-4F if SPEER-4F is regulated downstream of mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which is crucial for the activation of the AKT signaling pathway. By inhibiting PI3K, LY294002 could lead to reduced phosphorylation and activation of AKT, which in turn may result in decreased functional activity of SPEER-4F if SPEER-4F is a downstream target of the PI3K/AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. By inhibiting MEK, U0126 prevents the activation of ERK, which may lead to the inhibition of transcription factors and downstream genes that could include SPEER-4F if it is regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 can disrupt inflammatory responses and other cellular processes mediated by this kinase, which could indirectly affect the functional activity of SPEER-4F if SPEER-4F is modulated by signals that involve p38 MAPK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor similar to U0126, and it works by preventing the activation of MAPK/ERK pathway. By doing so, it could lead to reduced activity of SPEER-4F if SPEER-4F is involved in signaling pathways or cellular processes downstream of the ERK pathway. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective inhibitor of EGFR with T790M mutation, which confers resistance to first-generation EGFR inhibitors. By specifically targeting this mutation, WZ4002 can inhibit EGFR signaling and potentially decrease the functional activity of SPEER-4F if SPEER-4F is regulated by pathways involving EGFR. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which alters transcription factor activity and gene expression. Inhibition of JNK by SP600125 could result in decreased functional activity of SPEER-4F if SPEER-4F is downstream of JNK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that affects numerous cellular processes by preventing the degradation of ubiquitinated proteins. This could lead to decreased functional activity of SPEER-4F if SPEER-4F is stabilized by ubiquitination and subsequent degradation through the proteasome. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several tyrosine protein kinases such as VEGFR and PDGFR, and the serine/threonine kinase RAF-1. By inhibiting these kinases, sorafenib could reduce the functional activity of SPEER-4F if SPEER-4F is regulated by these kinases or their downstream signaling cascades. | ||||||